間質液中の臨床的に関連性のあるグルコースを検出するための使い捨てマイクロニードルバイオセンサー

Effective diabetes management is increasingly shifting toward minimally invasive technologies that enable frequent and reliable assessment of glucose levels in interstitial fluid (ISF), enabling more informed and patient-centered monitoring. However, current approaches to glucose detection rely heavily on invasive blood-based glucometers or complex wearable devices for continuous monitoring. This study introduces a complete biosensing system using a novel swellable biocompatible microneedle (MN) array combined with chemically modified screen-printed electrodes (SPEs). Optimization of ISF collection was achieved using a customized applicator with variable vibration, which resulted in ISF uptake of 6.55 ± 0.47 μL (0Hz) and 7.06 ± 0.44 μL (100 Hz) within 5 min of application. The Prussian Blue/chitosan-SWCNT/GO_x/Nafion-modified SPE shows excellent sensitivity of 12.26 μA mM^-1 cm^-2, a detection limit of 0.08 mM, and high selectivity against common ISF interferents. In vitro and ex vivo validation across clinically relevant glucose concentrations showed strong linearity (R² = 0.989 and 0.978, respectively), with recovery exceeding 70 % in vitro and 50 % ex vivo compared with a commercial glucometer. This minimally invasive MN SPE platform enables reliable glucose quantification from microliter ISF volumes and shows strong potential for future multi-biomarker, point-of-care monitoring.